One of the Oxford Doctors in full PPE, Sierra Leone 2015, Port Loko. Credit: Rebecca Inglis
We have developed a several open access resources to enable global standardised clinical data collection, research and training. Alongside these, we have clinical data reports that are updated regularly thanks to the efforts of the contributors to our ever-growing data base.
We have recently launched a study on Long COVID and welcome interested sites to join this study aiming to identify prevalent symptoms after hospital discharge.
We are currently conducting a randomised controlled trial to compare two treatment regimens for plague. This trial is being conducted in rural health centres across Madagascar. Several patients have already been enrolled and we are expecting to reach our sample size of 190 confirmed or probable cases by March 2022.
We are in the process of developing a clinical trial framework for Lassa fever.
In collaboration with leading experts in the field of Lassa Fever, this project aims to establish, among other components, a Core Outcome Set and Core Data Variables for use in future clinical trials. It is expected that this project will be completed by the end of December 2020.
We are aiming to set-up an expanded access protocol for patients diagnosed with monkeypox. This project is in the early stages of development and further details will be released at a later date.
(Short PeRiod IncideNce sTudy of Severe Acute Respiratory Infection)
An effective epidemic response depends on how well prepared we are. This starts before the pandemic begins. The ISARIC SPRINT-SARI study is a global prospective observational study that has been enrolling patients with severe acute respiratory infections since 2015, increasing knowledge of these infections in inter-epidemic times, in preparation for a future pandemic.
The study is currently on hold whilst ISARIC focusses on COVID-19. For more information on SPRINT-SARI contact firstname.lastname@example.org
Severe Acute Hepatitis
The ISARIC Global Support Centre has consulted with a number of agencies working on severe acute hepatitis of unknown aetiology in children. ISARIC’s global position is to work with the World Health Organization (WHO) on a data collection tool to ensure international standardised data collection, should it be required.